Skip to Content
Merck
CN

PZ0006

Exemestane

≥98% (HPLC)

Synonym(s):

6-Methyleneandrosta-1,4-diene-3,17-dione

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C20H24O2
CAS Number:
107868-30-4
Molecular Weight:
296.40
NACRES:
NA.77
PubChem Substance ID:
329823675
UNSPSC Code:
51111800
MDL number:
MFCD00866994

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Exemestane, ≥98% (HPLC)

InChI

1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1

SMILES string

C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O

InChI key

BFYIZQONLCFLEV-DAELLWKTSA-N

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +250 to +300°, c = 1 in methanol

color

white to off-white

solubility

DMSO: ≥20 mg/mL

storage temp.

2-8°C

Quality Level

100

Gene Information

human ... CYP19A1(1588)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Exemestane is a steroidal antiestrogen and irreversible aromatase inhibitor. Exemestane acts as a false substrate for the aromatase enzyme. Exemestane also prevents the conversion of androgens to estrogens and is used to treat estrogen-dependent breast cancer.
Exemestane is a steroidal antiestrogen; aromatase inhibitor.

Features and Benefits

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

hcodes

H360,H411

pictograms

Health hazardEnvironment
GHS08,GHS09

signalword

Danger

Hazard Classifications

Aquatic Chronic 2 - Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

涉药品监管产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000362182
0000362182
037M4720V
100M4705

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Willemien van de Water et al.
The oncologist, 18(1), 8-13 (2012-12-25)
For postmenopausal patients with hormone-sensitive breast cancer, outcome is worse with increasing age at diagnosis. The aim of this study was to assess the incidence of breast cancer recurrence (locoregional and distant), and contralateral breast cancer by age at diagnosis.
Nan Soon Wong et al.
Expert opinion on pharmacotherapy, 6(13), 2353-2363 (2005-10-13)
Breast cancer is a major health problem in developed countries. Endocrine therapy is a key component in the management of hormone receptor-positive disease. Although tamoxifen has historically been the gold standard in the first-line management of early and advanced breast
Willemien van de Water et al.
European journal of cancer (Oxford, England : 1990), 49(2), 297-304 (2012-09-08)
Multiple studies suggest better efficacy of chemotherapy in invasive ductal breast carcinomas (IDC) than invasive lobular breast carcinomas (ILC). However, data on efficacy of adjuvant endocrine therapy regimens and histological subtypes are sparse. This study assessed endocrine therapy efficacy in
Elizabeth Maunsell et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(14), 1427-1436 (2014-04-09)
Exemestane, a steroidal aromatase inhibitor, reduced invasive breast cancer incidence by 65% among 4,560 postmenopausal women randomly assigned to exemestane (25 mg per day) compared with placebo in the National Cancer Institute of Canada (NCIC) Clinical Trials Group MAP.3 (Mammary
John Fr Robertson et al.
The Lancet. Oncology, 14(3), 228-235 (2013-02-19)
Insulin-like growth factors (IGF-1 and IGF-2) bind to the IGF-1 receptor (IGF-1R), increasing cell proliferation and survival. Ganitumab is a monoclonal IgG1 antibody that blocks IGF-1R. We tested the efficacy and safety of adding ganitumab to endocrine treatment for patients
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service